Stage IV lung adenocarcinoma — complete response and long-term survival

The article presents the case of a 52-year-old patient (currently 61 years old) diagnosed with stage IIa non-smallcell adenocarcinoma of the left lung. The patient underwent surgical resection with negative margins (R0) and received adjuvant chemotherapy with cisplatin and vinorelbine (PN regimen). One year later, a relapse occurred with a solitary brain metastasis, indicating disease progression to stage IV. Stereotactic radiotherapy using the Gamma Knife technique was performed, followed by systemic treatment with cisplatin and gemcitabine (PG regimen), which was discontinued due to poor tolerance. Subsequently, an immunotherapy with nivolumab was administered and complete response was achieved after 51 treatment cycles. As of the date of publication, no recurrence has been observed, with the patient remaining in remission for six years. He is professionally active, reports no symptoms, and continues outpatient follow-up. This case highlights the importance of personalized therapy, the critical role of clinical trials in expanding treatment options for oncology patients, and the growing significance of immunotherapy in the management of advanced non-small-cell lung cancer.